Oral S-1 May Be Non-Inferior to Docetaxel for Non-Small Cell Lung Cancer

Share this content:
Oral S-1 with cisplatin may not be inferior compared to docetaxel with cisplatin in advanced NSCLC.
Oral S-1 with cisplatin may not be inferior compared to docetaxel with cisplatin in advanced NSCLC.

Oral S-1 with cisplatin may not be inferior and could be better tolerated compared to docetaxel with cisplatin in patients with advanced non-small cell lung cancer (NSCLC), according to a study conducted in a Japanese population and published in Annals of Oncology.

Researchers led by Kaoru Kubota, MD, of the Nippon Medical School in Tokyo examined 608 patients with previously untreated stage IIIB or IV NSCLC who were randomized to receive either oral S-1 with cisplatin or docetaxel with cisplatin.

“The primary aim was to compare overall survival of patients with advanced NSCLC between the two chemotherapy regimens,” the authors noted.

RELATED: Pembrolizumab Safe, Shows Activity for Advanced Lung Cancer

They found that overall survival for oral S-1 with cisplatin was non-inferior to docetaxel with cisplatin, although there were no differences in progression-free survival or response between the two groups.

In addition, there were significantly higher rates of febrile neutropenia, infection and alopecia in the docetaxel plus cisplatin group.

Quality of life data investigating by the European Organization for Research and Treatment of Cancer favored the S-1 plus cisplatin treatment.


  1. Kubota, K., et al. "A Randomized Phase III Trial of Oral S-1 plus Cisplatin versus Docetaxel plus Cisplatin in Japanese Patients with Advanced Non-small-cell Lung cancer: TCOG0701 CATS TRIAL." Annals of Oncology. doi: 10.1093/annonc/mdv190. [epub ahead of print]. April 23, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs